Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 3.54% is 49% above its 5-year average of 2.38%, near the high end of its 5-year range (-0.57%–4.76%).
2.75% below its 12-month average of 3.64%.
Annual fiscal-year return on assets; no daily interpolation. Historical series through 2025-12-31.
RETURN ON ASSETS (ROA)
3.54%
RETURN ON ASSETS (ROA) AVG TTM
3.64%
RETURN ON ASSETS (ROA) AVG 3Y
3.29%
RETURN ON ASSETS (ROA) AVG 5Y
2.38%
RETURN ON ASSETS (ROA) AVG 10Y
2.36%
RETURN ON ASSETS (ROA) AVG 15Y
4.13%
RETURN ON ASSETS (ROA) AVG 20Y
5.98%
CURRENT VS TTM AVG
-2.75%
CURRENT VS 3Y AVG
+7.76%
CURRENT VS 5Y AVG
+48.74%
CURRENT VS 10Y AVG
+50.00%
CURRENT VS 15Y AVG
-14.38%
CURRENT VS 20Y AVG
-40.77%
SECTOR MEDIAN · HEALTHCARE
5.14%
median of 90 covered companies
CURRENT VS SECTOR MEDIAN
-31.13%
vs the sector median at left
Zimmer Biomet Holdings, Inc.
Market Cap
$18.33B
Return on Assets (ROA)
3.54%
TTM Avg
3.64%
3Y Avg
3.29%
5Y Avg
2.38%
Market Cap
$17.07B
Return on Assets (ROA)
23.89%
TTM Avg
21.05%
3Y Avg
19.32%
5Y Avg
16.45%
Market Cap
$19.82B
Return on Assets (ROA)
-1.17%
TTM Avg
-5.49%
3Y Avg
-1.68%
5Y Avg
-1.68%
Market Cap
$16.05B
Return on Assets (ROA)
1.97%
TTM Avg
2.19%
3Y Avg
1.89%
5Y Avg
3.83%
Market Cap
$21.02B
Return on Assets (ROA)
18.16%
TTM Avg
16.59%
3Y Avg
14.73%
5Y Avg
13.22%
Market Cap
$15.28B
Return on Assets (ROA)
10.07%
TTM Avg
7.10%
3Y Avg
8.43%
5Y Avg
7.35%
Market Cap
$14.63B
Return on Assets (ROA)
34.50%
TTM Avg
22.59%
3Y Avg
17.42%
5Y Avg
13.40%
Market Cap
$13.34B
Return on Assets (ROA)
-3.17%
TTM Avg
-0.94%
3Y Avg
2.58%
5Y Avg
3.75%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zimmer Biomet Holdings, Inc. (ZBH) | $18.33B | 3.54% | 3.64% | 3.29% | 2.38% |
| Medpace Holdings, Inc. (MEDP)vs › | $17.07B | 23.89% | 21.05% | 19.32% | 16.45% |
| Viatris Inc. (VTRS)vs › | $19.82B | -1.17% | -5.49% | -1.68% | -1.68% |
| STERIS plc (STE)vs › | $20.03B | 7.50% | 6.68% | 4.44% | 4.33% |
| Revvity, Inc. (RVTY)vs › | $16.05B | 1.97% | 2.19% | 1.89% | 3.83% |
| United Therapeutics Corporation (UTHR)vs › | $21.02B | 18.16% | 16.59% | 14.73% | 13.22% |
| Solventum Corporation (SOLV)vs › | $15.28B | 10.07% | 7.10% | 8.43% | 7.35% |
| Exelixis, Inc. (EXEL)vs › | $14.63B | 34.50% | 22.59% | 17.42% | 13.40% |
| Charles River Laboratories International, Inc. (CRL)vs › | $13.34B | -3.17% | -0.94% | 2.58% | 3.75% |
| Tempus AI, Inc. (TEM)vs › | $13.33B | -10.75% | -43.49% | -42.71% | -41.26% |
ROA
3.5%
ROE
6.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 3.05% |
| 2024-12-31 | 4.23% |
| 2023-12-31 | 4.76% |
| 2022-12-31 | 1.10% |
| 2021-12-31 | 1.71% |
| 2020-12-31 | -0.57% |
| 2019-12-31 | 4.59% |
| 2018-12-31 | -1.57% |
| 2017-12-31 | 6.97% |
| 2016-12-31 | 1.15% |
| 2015-12-31 | 0.54% |
| 2014-12-31 | 7.48% |
| 2013-12-31 | 7.94% |
| 2012-12-31 | 8.38% |
| 2011-12-31 | 8.93% |
| 2010-12-31 | 7.46% |
| 2009-12-31 | 9.21% |
| 2008-12-31 | 11.72% |
| 2007-12-31 | 11.66% |
| 2006-12-31 | 13.97% |
| 2005-12-31 | 12.80% |
| 2004-12-31 | 9.51% |
| 2003-12-31 | 6.72% |
| 2002-12-31 | 30.02% |
| 2001-12-31 | 20.11% |
| 2000-12-31 | 29.46% |
| 1999-12-31 | 24.75% |
| 1998-12-31 | 0.00% |
